Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  antibody-drug conjugate therapy
Results 1-25 of 111 for your search:
Start Over
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Status: Active
Phase: Phase IV
Type: Treatment
Age: 3 months and over
Trial IDs: B1761026, NCI-2015-00700, NCT02312037
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-014, NCI-2013-00462, 2012-002751-42, NCT01777152
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-204, NCI-2016-00839, 2015-005053-12, 163337, NCT02684292
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 2010-0991, NCI-2011-01123, NCT01371630
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-130-02, NCI-2013-01786, NCT01605318
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Brentuximab Vedotin and Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAJ5050, NCI-2012-01926, NCT01657331
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-085, NCI-2013-00046, 085, 2014-003678-18, NCT01771107
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: AHOD1221, NCI-2013-00107, COG-AHOD1221, NCT01780662
Brentuximab Vedotin and Rituximab in Treating Patients with Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Untreated Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma or Gray Zone Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 17413, NCI-2013-02359, 818280, NCT01994850
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 45 and under
Trial IDs: NYMC 564, NCI-2015-01809, NCT02098512
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9111, NCI-2014-01782, NCT02227199
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29365, NCI-2015-00293, 2014-001361-28, NCT02257567
Bosutinib and Inotuzumab Ozogamicin in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0435, NCI-2014-02606, NCT02311998
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-10, NCI-2015-00275, NCT02236000
A Phase I/IIa Study of BMS-986148 in Subjects With Select Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA008-002, NCI-2015-01329, 2014-002485-70, NCT02341625
DT2219 Immunotoxin in Treating Patients with Relapsed or Refractory B-Cell Leukemia or Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2014LS093, NCI-2015-00555, HM2014-26, NCT02370160
Mocetinostat and Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-232, NCI-2015-00780, NCT02429375
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-025, NCI-2015-01867, NCT02572167
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: SGN33A-003, NCI-2015-02237, NCT02614560
Start Over